German Bundesrat insists on 'real price' disclosure
This article was originally published in Scrip
Executive Summary
With the pharmaceutical industry increasingly seeking reimbursement on the basis of 'real-world data' on effectiveness, German politicians are now insisting on transparency on 'real prices' for drugs. On 21 September, the Bundesrat, German's Federal Council which has to endorse legislation administered by the country's regional governments, formally approved amendments to the AMNOG healthcare reform law that mean that any price discounts negotiated between pharmaceutical companies and health insurers in Germany will be publically available.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.